Technologies

The GI Company is currently focusing on two key technologies:

Intestinal Trefoil Factor for mucosal repair

Orphanin Analogues to treat gastrointestinal motility disorders

The company has given a high priority to the development of a recombinant human intestinal trefoil factor to spearhead the early stages of growth. The company is establishing partnerships to accelerate the discovery of orphanin analogues and the development of asiolo-interferon.

Through a network of collaborating institutions, The GI Company has access to novel technologies in early stages of development to enhance its pipeline and product portfolio.